DETECTION OF P16INK4A PROMOTER METHYLATION IN THE BLOOD SAMPLE COMPARED WITH CLINICO-PATHOLOGICAL FINDINGS OF CERVICAL CANCER PATIENTS: A NORTH INDIAN STUDY
Amita Gupta, Md. Kaleem Ahmad, Abbas Ali Mahndi, Renu Singh, Yashodhara Pradeep*
Epidemiologic and clinical data show that the development of cervical cancer is a multifactorial process in which infection with human papillomavirus (HPV) takes a central place along with other risk factors such as smoking, immunosuppression, immunodeficiency, diet, parity, age at first full-term pregnancy and family history. Detection of p16 Methylation in Blood Samples Compared with Clinicopathological
findings analyzed in the north India population among cervical cancer patients. Methylation status of p16 promoter was analysed in cervical cancer and controls subjects by PCR using specific primer for p16 after methylation-insensitive restriction enzyme digestion of genomic DNA. Methylated status of p16 gene promoter was analysed in cervical cancer cases and controls using RE digestion followed by PCR. The methylation-insensitive restriction enzymes cut regions containing unmethylated CpG sequences at the promoter region. Methylation pattern analysis of cervical cancer out of 64 cases 51(79.7%) of them contained methylated CpG island at promoter region compare to controls containing only 13(40.6%) out of 32 subjects methylated CpG. It was observe that methylated p16 promoter subjects have higher risk of cervical cancer in comparison with unmethylated p16 promoter subjects. This result supports that p16 methylation in blood could be a novel marker for the malignancy of cervical cancer.
Keywords: Cervical Cancer, Methylation, p16, north Indian population.
[Full Text Article]